Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors: Pharmadodynamic Comparison Between Prasugrel and Ticagrelor Monotherapy. The Switching Antiplatelet -7 (SWAP-7) Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
• Age between 18 and 75 years old
• Able to provide written informed consent
Locations
United States
Florida
University of Florida Jacksonville
RECRUITING
Jacksonville
Contact Information
Primary
Francesco Franchi, MD
francesco.franchi@jax.ufl.edu
9042445515
Backup
Andrea Burton
andrea.burton@jax.ufl.edu
(904) 244-5617
Time Frame
Start Date: 2025-01-08
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 48
Treatments
Active_comparator: Ticagrelor monotherapy
Ticagrelor 90 mg bid monotherapy for 21±7 days
Experimental: Prasugrel monotherapy
Prasugrel 10 mg qd for 21±7 days
Related Therapeutic Areas
Sponsors
Leads: University of Florida